News

Euclid Vision Announces Acquisition of Visionary Optics

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution pioneer. The acquisition signifies Euclid’s recognition of the value of joining forces with Visionary Optics, the only company in the US that concentrates almost exclusively on scleral contact lenses. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.

“We are excited about joining forces with Visionary Optics. This union opens exciting opportunities for cross-company collaboration and innovation,” said Joseph Boorady, Euclid President and CEO. “Visionary Optics, with its best-in-class scleral lens innovations and world class customer service, is a great match for the Euclid portfolio. Having market leading technologies in two of the fastest growing specialty contact lens markets — Ortho-K and scleral lenses — positions us to better serve our customers and their patients.”

Euclid and Visionary Optics share many of the same cultural values, such as a dedication to professional education, strong partnerships with eye care professionals, and market savvy product innovation. Each company will retain their unique individual brand, while being perfectly positioned to reap the benefits of shared future endeavors.

“This is an incredible opportunity for Visionary Optics to work with a partner who can help take our business and technology to the next level, while also maintaining the key foundational aspects of what has fueled our success including our customer-driven corporate culture and high-tech research orientation,” said Donald Sanders, MD, PhD Visionary Optics President and CEO.

Euclid and Visionary Optics understand that clinicians partner with companies that not only offer unparalleled lens design and the highest-level of advanced manufacturing, but those that also provide exceptional customer service. “Expert customer service is critical to the success of the clinicians who work with us, and we pride ourselves on the level of expertise for which our customer service team is known,” said Dr. Sanders. “As we unite with Euclid, preserving these team values are integral to maintaining our role as a leader in scleral lens design and distribution. Thus, our customers can count on the same great service they are used to with Visionary Optics.”

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients